Skip to content

Effect of pre-medication with beta blockers on scan time and imaging quality in patients having CT coronary angiography

A prospective observational cohort study evaluating the effect of pre-medication with beta blockers on imaging qualty, scan cancellation rate, and arrival to scan time in patients undergoing CT coronary angiography at the Victorian Heart hospital

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12625001138471
Enrollment
360
Registered
2025-10-17
Start date
2025-11-15
Completion date
2026-03-28
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study looks at when beta blockers are given to patients having a CT coronary angiogram (CTCA). Some patients take beta blockers before arriving for their scan, while others receive them once they are in the imaging deparement. The purpose of this study is to compare how these two approaches affect scan preparation and timing. we think that giving beta blockers before arrival will reduce delays and make the process smoother.

Interventions

exposure: timing of beta blocker administration for patients undergoing CTCA. pre-medication group: patients who were instructed to take oral beta blockers prior to arrival at the imaging department. Clarification: Timing of beta blocker administration is determined by standard clinical practice for each group. The decision regarding whether participants take oral beta blocker prior to arrival at the imaging department will be made by the referring cardiologist. The decision is based on the c

exposure: timing of beta blocker administration for patients undergoing CTCA. pre-medication group: patients who were instructed to take oral beta blockers prior to arrival at the imaging department. Clarification: Timing of beta blocker administration is determined by standard clinical practice for each group. The decision regarding whether participants take oral beta blocker prior to arrival at the imaging department will be made by the referring cardiologist. The decision is based on the cardiologist's assessment of the individual patient, as well as their own judgement and practice preferences. Some cardiologists routinely prepare patients with oral beta blockers before CTCA to optimise heart rate control, while others prefer to leave rate control to be managed on-site. Participants who have been advised by their cardiologist to take oral beta blockers before the scan will form the premedicated group, while those who have not will form the stardard care group ( non-premedicated group). The rationale for asking participants to take oral beta blockers prior to arrival is to allow sufficient time for the medication to take effect, ensuring optimal heart rate reduction before CTCA imaging. Achieving a stable heart rate of <60bpm improves image quality and diagnostic accuracy by reducing cardiac motion artefacts. Pre-arrival beta blocker administration also minimises on-site preparation time and supports efficient workflow. Data collected from electronic medical records and radiation information system include heart rate and blood pressure at time of admission and at the time of scanning, type of beta blockers and administration time, CTCA scan quality, completion and relevant patient demographics ( Age, gender, hight and weight). No additional interventions are required for the study. Participants follow standard clinical procedures for CTCA preparation, no additional procedures are required for study purposes. It is only one time data collection, no long term follow-up is requried.

Sponsors

Victorian Heart Hospital
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1) adults aged over 18 years referred for CTCA 2) able to provide informed consent

Exclusion criteria

1) current therapy with non-dihydropyridine calcium channel blockers 2) contraindication to beta blockers 3) haemodynamically unstable 4) inability to provide informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026